Cowealth Medical Holding (4745) reported revenue of NT$183.7 million for Oct 2026, +12.5% year on year and -46.9% from the previous month. Revenue for Jan–Oct 2026 was NT$2.56 billion (+0.4% year on year).
In Oct 2026, it ranked No. 45 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$183.7 million | +12.5% | -46.9% |
| Sep 2026 | NT$345.7 million | +27.4% | +52.7% |
| Aug 2026 | NT$226.4 million | -13.3% | -7.8% |
| Jul 2026 | NT$245.5 million | +2.6% | -28.6% |
| Jun 2026 | NT$343.8 million | +39.6% | +54.5% |
| May 2026 | NT$222.6 million | -10.9% | -22.6% |
| Apr 2026 | NT$287.5 million | -10.9% | +11.3% |
| Mar 2026 | NT$258.4 million | -14.3% | +25.6% |
| Feb 2026 | NT$205.7 million | -9.7% | -13.6% |
| Jan 2026 | NT$238.1 million | -10.2% | -12.2% |
| Dec 2025 | NT$271.3 million | -32.9% | +46.9% |
| Nov 2025 | NT$184.6 million | -47.3% | +13.1% |
| Oct 2025 | NT$163.2 million | -39.6% | -39.9% |
| Sep 2025 | NT$271.4 million | -32.1% | +4.0% |
| Aug 2025 | NT$261 million | -20.0% | +9.1% |
| Jul 2025 | NT$239.2 million | -23.3% | -2.8% |
| Jun 2025 | NT$246.2 million | -27.0% | -1.4% |
| May 2025 | NT$249.7 million | -23.7% | -22.6% |
| Apr 2025 | NT$322.6 million | -23.1% | +7.0% |
| Mar 2025 | NT$301.4 million | -23.0% | +32.3% |
| Feb 2025 | NT$227.8 million | -5.1% | -14.1% |
| Jan 2025 | NT$265.2 million | -36.1% | -34.4% |
| Dec 2024 | NT$404.1 million | -20.8% | +15.4% |
| Nov 2024 | NT$350.1 million | +10.4% | +29.6% |
| Oct 2024 | NT$270.1 million | -20.6% | -32.4% |
Jan–Oct 2026 cumulative: NT$2.56 billion (+0.4% YoY)
Other Biotech & Medical companies
Compare with peers: Cowealth Medical Holding vs PEC / Cowealth Medical Holding vs Lotus Pharm / Cowealth Medical Holding vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
公司2026年1-10月合併營業收入較去年同期增加0.38%,營收狀況改善。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16